Cargando…

Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor

Detalles Bibliográficos
Autores principales:	Zhang, Huifang, Huang, Zineng, He, Liyu, Yuan, Fang, Sun, Lin, Liu, Fuyou, Xiao, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472505/ https://www.ncbi.nlm.nih.gov/pubmed/32814474 http://dx.doi.org/10.1080/0886022X.2020.1803087

Ejemplares similares

Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia
por: Zheng, Li, et al.
Publicado: (2022)

Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
por: Li, Jing, et al.
Publicado: (2022)

Hypoxia-inducible factor prolyl hydroxylase inhibitors in kidney transplant recipients
por: Ogata, Masatomo, et al.
Publicado: (2022)

Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitors for the Treatment of Anemia in CKD: Additional Pieces of the Jigsaw Puzzle
por: Wish, Jay B.
Publicado: (2021)

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism
por: Ogawa, Chie, et al.
Publicado: (2023)

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state
por: Joharapurkar, Amit A., et al.
Publicado: (2022)

Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
por: Chen, Nan, et al.
Publicado: (2017)

A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat
por: Yan, Zhipeng, et al.
Publicado: (2020)

Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in heart failure patients: A protocol for systematic review and meta-analysis
por: Fukuta, Hidekatsu, et al.
Publicado: (2022)

A Novel Prolyl Hydroxylase Inhibitor Protects Against Cell Death After Hypoxia
por: Kontani, Satoru, et al.
Publicado: (2013)

Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications
por: Kim, So Yeon, et al.
Publicado: (2015)

Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases
por: Miao, Mengqiu, et al.
Publicado: (2022)

Structure–Activity Relationships and Transcriptomic Analysis of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors
por: Poloznikov, Andrey A., et al.
Publicado: (2022)

Cloning of the Human MORG1 Promoter: Differential Regulation by Hypoxia and Prolyl-Hydroxylase Inhibitors
por: Bondeva, Tzvetanka, et al.
Publicado: (2022)

Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?
por: Chou, Yu-Hsiang, et al.
Publicado: (2023)

Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease
por: Lun, Jie, et al.
Publicado: (2023)

Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor
por: Kiriakidis, Serafim, et al.
Publicado: (2017)

Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Renal Function in Patient with Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Heart Failure with Preserved Ejection Fraction
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Assessing the Carcinogenicity of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, in Rodents
por: Kowalski, Heather, et al.
Publicado: (2023)

An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease
por: Zhao, Hanxue, et al.
Publicado: (2023)

Neuroprotective Effect of HIF Prolyl Hydroxylase Inhibition in an In Vitro Hypoxia Model
por: Savyuk, Maria, et al.
Publicado: (2020)

Gas tunnel engineering of prolyl hydroxylase reprograms hypoxia signaling in cells
por: Windsor, Peter, et al.
Publicado: (2023)

Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients
por: Wang, Bin, et al.
Publicado: (2020)

An Overview of Safety and Efficacy Between Hypoxia-Inducible Factor-Prolyl-Hydroxylase Inhibitors and Erythropoietin-Stimulating Agents in Treating Anemia in Chronic Kidney Disease Patients
por: Sonia, Shamsun Nahar, et al.
Publicado: (2023)

The Hypoxia-Inducible Factor Pathway, Prolyl Hydroxylase Domain Protein Inhibitors, and Their Roles in Bone Repair and Regeneration
por: Fan, Lihong, et al.
Publicado: (2014)

Potent and Selective Triazole-Based Inhibitors of the Hypoxia-Inducible Factor Prolyl-Hydroxylases with Activity in the Murine Brain
por: Chan, Mun Chiang, et al.
Publicado: (2015)

Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor Improves Leukocyte Energy Metabolism in Hereditary Hemorrhagic Telangiectasia
por: Schild, Yves, et al.
Publicado: (2023)

The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors
por: Locatelli, Francesco, et al.
Publicado: (2023)

Tuning the Transcriptional Response to Hypoxia by Inhibiting Hypoxia-inducible Factor (HIF) Prolyl and Asparaginyl Hydroxylases
por: Chan, Mun Chiang, et al.
Publicado: (2016)

Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence
por: Fujikawa, Ryo, et al.
Publicado: (2022)

Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis
por: Chen, Dinghua, et al.
Publicado: (2023)

Four Cases of Serum Copper Excess in Patients with Renal Anemia Receiving a Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor: A Possible Safety Concern
por: Nakamura, Hironori, et al.
Publicado: (2022)

Microbiota-derived butyrate is an endogenous HIF prolyl hydroxylase inhibitor
por: Wang, Ruth X., et al.
Publicado: (2021)

Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
por: Groenendaal-van de Meent, Dorien, et al.
Publicado: (2016)

Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
por: Groenendaal-van de Meent, Dorien, et al.
Publicado: (2020)

The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia
por: Landau, Daniel, et al.
Publicado: (2018)

Whether Prolyl Hydroxylase Blocker—Roxadustat—In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future?
por: Grzeszczak, Władysław, et al.
Publicado: (2021)

Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials
por: Yeh, Tzu-Lan, et al.
Publicado: (2017)

Studies on spiro[4.5]decanone prolyl hydroxylase domain inhibitors
por: Holt-Martyn, James P., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_20kf3mc16qa0sfcgvbi114t9ip